Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document foreign issuer current reports, oncology program updates, financing transactions, governance changes, and liquidity-related disclosures. The company furnishes Form 6-K reports and references Form 20-F reporting status, with exhibits covering financial results, clinical updates for vebreltinib, and corporate developments affecting ongoing operations.
The filing record also covers material agreements, related-party convertible note financing, PIPE share issuance, resale registration obligations, board and committee appointments, proxy materials, and risk disclosures tied to cash resources, collaboration payments, Nasdaq listing compliance, and the company’s capital structure as a Cayman Islands issuer with Class A ordinary shares and warrants.
Apollomics Inc. Chief Financial Officer Peter Kuan-How Lin reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 10,000 RSUs vested into Class A Ordinary Shares, reflecting previously granted awards that vest in four 10,000-share installments.
In connection with this vesting, 3,588 Class A Ordinary Shares were disposed of to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Lin held 25,900 Class A Ordinary Shares directly. The filing reflects compensation-related equity settlement, not a discretionary market purchase or sale.
Apollomics Inc. Chief Financial Officer Peter Kuan-How Lin reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 10,000 RSUs vested into Class A Ordinary Shares, reflecting previously granted awards that vest in four 10,000-share installments.
In connection with this vesting, 3,588 Class A Ordinary Shares were disposed of to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Lin held 25,900 Class A Ordinary Shares directly. The filing reflects compensation-related equity settlement, not a discretionary market purchase or sale.
Apollomics Inc. director and CEO Hung-Wen Chen reported equity compensation activity rather than open‑market trading. On June 15, 2026, 5,000 Restricted Stock Units vested, and he acquired 5,000 Class A Ordinary Shares at a price of $0.00 per share through a derivative exercise. Each RSU converts into one Class A Ordinary Share.
Following the transaction, Chen directly holds 148,334 Class A Ordinary Shares and has an indirect interest in 763,028 Class A Ordinary Shares held through King Regent Management Limited, where he has voting and dispositive power but disclaims beneficial ownership except for his pecuniary interest. After this vesting, 5,000 RSUs remain from the original grant, scheduled to vest on September 15, 2026.
Apollomics Inc. director and CEO Hung-Wen Chen reported equity compensation activity rather than open‑market trading. On June 15, 2026, 5,000 Restricted Stock Units vested, and he acquired 5,000 Class A Ordinary Shares at a price of $0.00 per share through a derivative exercise. Each RSU converts into one Class A Ordinary Share.
Following the transaction, Chen directly holds 148,334 Class A Ordinary Shares and has an indirect interest in 763,028 Class A Ordinary Shares held through King Regent Management Limited, where he has voting and dispositive power but disclaims beneficial ownership except for his pecuniary interest. After this vesting, 5,000 RSUs remain from the original grant, scheduled to vest on September 15, 2026.
Apollomics Inc. director CHU YI-AN acquired 500 Class A Ordinary Shares through the vesting and exercise of Restricted Stock Units (RSUs). The shares were issued at a price of $0.00 per share as part of previously granted equity awards.
Following this transaction, CHU YI-AN directly holds 1,500 Class A Ordinary Shares. The footnotes state that the initial RSU grant vested in four equal tranches of 500 shares, with three tranches (including this one on June 15, 2026) already vested and an additional 500 RSUs scheduled to vest on September 15, 2026.
Apollomics Inc. director CHU YI-AN acquired 500 Class A Ordinary Shares through the vesting and exercise of Restricted Stock Units (RSUs). The shares were issued at a price of $0.00 per share as part of previously granted equity awards.
Following this transaction, CHU YI-AN directly holds 1,500 Class A Ordinary Shares. The footnotes state that the initial RSU grant vested in four equal tranches of 500 shares, with three tranches (including this one on June 15, 2026) already vested and an additional 500 RSUs scheduled to vest on September 15, 2026.
Apollomics Inc. director Hong-Jung Chen exercised restricted stock units into common shares. On June 15, 2026, 500 Restricted Stock Units converted into 500 Class A Ordinary Shares at a stated price of $0.00 per share, increasing direct holdings to 3,620 Class A Ordinary Shares.
The RSUs were part of a previously disclosed grant. Footnotes explain that 500 RSUs vested on each of February 9, 2026, March 15, 2026 and June 15, 2026, and an additional 500 RSUs are scheduled to vest on September 15, 2026.
Apollomics Inc. director Hong-Jung Chen exercised restricted stock units into common shares. On June 15, 2026, 500 Restricted Stock Units converted into 500 Class A Ordinary Shares at a stated price of $0.00 per share, increasing direct holdings to 3,620 Class A Ordinary Shares.
The RSUs were part of a previously disclosed grant. Footnotes explain that 500 RSUs vested on each of February 9, 2026, March 15, 2026 and June 15, 2026, and an additional 500 RSUs are scheduled to vest on September 15, 2026.
Apollomics Inc. director Tsai Hsien-Shu increased his direct equity stake through routine equity compensation. On June 15, 2026, 500 Restricted Stock Units vested, converting into 500 Class A Ordinary Shares at a price of $0.00 per share.
The RSUs were part of a prior grant under which 500 units vested on each of February 9, March 15, and June 15, 2026, with another 500 scheduled to vest on September 15, 2026. Following this transaction, Tsai directly holds 1,500 Class A Ordinary Shares and 500 remaining RSUs, reflecting standard compensation-related equity accrual rather than an open-market trade.
Apollomics Inc. director Tsai Hsien-Shu increased his direct equity stake through routine equity compensation. On June 15, 2026, 500 Restricted Stock Units vested, converting into 500 Class A Ordinary Shares at a price of $0.00 per share.
The RSUs were part of a prior grant under which 500 units vested on each of February 9, March 15, and June 15, 2026, with another 500 scheduled to vest on September 15, 2026. Following this transaction, Tsai directly holds 1,500 Class A Ordinary Shares and 500 remaining RSUs, reflecting standard compensation-related equity accrual rather than an open-market trade.
Apollomics Inc. director and COO Yi-Kuei Chen reported equity holdings and a routine RSU vesting. On June 15, 2026, he exercised 5,000 Restricted Stock Units at $0.00 per share, receiving 5,000 Class A Ordinary Shares, bringing his direct holdings to 15,000 shares.
He is also shown as having an indirect interest in 101,248 Class A Ordinary Shares through Maxpro Investment Co., Ltd., where he serves on the board and disclaims beneficial ownership except for his pecuniary interest. The RSUs involved in this filing were previously granted and disclosed on earlier Forms 3 and 3/A.
Apollomics Inc. director and COO Yi-Kuei Chen reported equity holdings and a routine RSU vesting. On June 15, 2026, he exercised 5,000 Restricted Stock Units at $0.00 per share, receiving 5,000 Class A Ordinary Shares, bringing his direct holdings to 15,000 shares.
He is also shown as having an indirect interest in 101,248 Class A Ordinary Shares through Maxpro Investment Co., Ltd., where he serves on the board and disclaims beneficial ownership except for his pecuniary interest. The RSUs involved in this filing were previously granted and disclosed on earlier Forms 3 and 3/A.
Apollomics Inc. director Jan Chen-Huan reported a routine equity compensation event, with 500 Restricted Stock Units vesting into 500 Class A Ordinary Shares on June 15, 2026. Each RSU represents a right to receive one Class A share. Following this vesting and related derivative exercise, Chen-Huan directly holds 1,500 Class A Ordinary Shares and 500 RSUs, with no open-market purchases or sales disclosed.
Apollomics Inc. director Jan Chen-Huan reported a routine equity compensation event, with 500 Restricted Stock Units vesting into 500 Class A Ordinary Shares on June 15, 2026. Each RSU represents a right to receive one Class A share. Following this vesting and related derivative exercise, Chen-Huan directly holds 1,500 Class A Ordinary Shares and 500 RSUs, with no open-market purchases or sales disclosed.
Apollomics Inc. director Huang Ya-Chi exercised restricted stock units that vested into common equity. On May 17, 2026, 500 Restricted Stock Units vested and were converted into 500 Class A Ordinary Shares at an exercise price of $0.00 per share.
Following this transaction, Huang directly holds 1,000 Class A Ordinary Shares. The RSU grant was previously disclosed, with 500 RSUs vesting on each of February 17, 2026 and May 17, 2026, and an additional 500 RSUs scheduled to vest on each of August 17, 2026 and November 17, 2026.
Apollomics Inc. director Huang Ya-Chi exercised restricted stock units that vested into common equity. On May 17, 2026, 500 Restricted Stock Units vested and were converted into 500 Class A Ordinary Shares at an exercise price of $0.00 per share.
Following this transaction, Huang directly holds 1,000 Class A Ordinary Shares. The RSU grant was previously disclosed, with 500 RSUs vesting on each of February 17, 2026 and May 17, 2026, and an additional 500 RSUs scheduled to vest on each of August 17, 2026 and November 17, 2026.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. reported full-year 2025 results showing its first revenue of $8.5M, driven by an upfront payment from the LaunXP licensing deal for vebreltinib in parts of Asia. The company sharply cut operating expenses to $19.8M from $55.7M, reducing its net loss to $10.9M (or $7.57 per diluted share) from $53.9M in 2024.
Cash, cash equivalents, bank deposits and money market funds were $3.3M as of December 31, 2025, down from $9.8M a year earlier, despite raising $4.1M via a PIPE in September 2025. The balance sheet showed a total equity deficit of $3.2M, reflecting accumulated losses. Strategically, Apollomics highlighted global Phase 2 development of its lead c-MET inhibitor vebreltinib, Chinese approvals for vebreltinib and PD-L1 antibody APL-502 in multiple indications, and a 2025 turnaround effort under a new management team with substantial cost reductions and resolution of legacy legal and clinical obligations.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.
Apollomics Inc. director Jan Chen-Huan has filed an amended ownership report showing equity awards and share holdings. The filing lists 1,000 Restricted Stock Units, each representing a contingent right to receive one Class A Ordinary Share. These RSUs are scheduled to vest in two equal installments of 500 shares on June 15, 2026 and September 15, 2026. The filing also reports direct ownership of 1,000 Class A Ordinary Shares following the reported positions.